Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response, particularly in recognizing and neutralizing pathogens such as bacteria and viruses. The specific variant mentioned, anti-(Staphylococcus aureus α-toxin), is designed to target the α-toxin produced by Staphylococcus aureus, a bacterium associated with various infections. This monoclonal antibody, MEDI4893, consists of heavy and light chains linked by disulfide bonds, forming a dimeric structure that enhances its stability and efficacy. The heavy chain is derived from human sources, ensuring better compatibility and reduced immunogenicity when used in therapeutic applications. The dimeric form allows for increased binding affinity and improved neutralization of the α-toxin, which is critical in preventing the cytotoxic effects associated with Staphylococcus aureus infections. Overall, this antibody represents a targeted therapeutic approach in managing infections caused by this pathogen, showcasing the advancements in monoclonal antibody technology for clinical use.

Immunoglobulin G1, anti-(Staphylococcus aureus α-toxin) (human monoclonal MEDI4893 heavy chain), disulfide with human monoclonal MEDI4893 κ-chain, dimer

1629620-18-3: Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response, particularly in recognizing and neutralizing pathogens such as bacteria and viruses. The specific variant mentioned, anti-(Staphylococcus aureus α-toxin), is designed to target the α-toxin produced by Staphylococcus aureus, a bacterium associated with various infections. This monoclonal antibody, MEDI4893, consists of heavy and light chains linked by disulfide bonds, forming a dimeric structure that enhances its stability and efficacy. The heavy chain is derived from human sources, ensuring better compatibility and reduced immunogenicity when used in therapeutic applications. The dimeric form allows for increased binding affinity and improved neutralization of the α-toxin, which is critical in preventing the cytotoxic effects associated with Staphylococcus aureus infections. Overall, this antibody represents a targeted therapeutic approach in managing infections caused by this pathogen, showcasing the advancements in monoclonal antibody technology for clinical use.

<p>Human monoclonal antibody targeting Staphylococcus aureus alpha toxin, prevention of nosocomial pneumonia</p>

Suvratoxumab

<p>Suvratoxumab (MEDI4893) is a long-lasting humanized IgG1κ monoclonal antibody targeting S. aureus α-toxin, enhancing survival in pneumonia.</p>

CAS 1629620-18-3

Immunoglobulin G1, anti-(Staphylococcus aureus α-toxin) (human monoclonal MEDI4893 heavy chain), disulfide with human monoclonal MEDI4893 κ-chain, dimer

Suvratoxumab

Ref: 3D-CLA1467

Suvratoxumab

Ref: TM-T76990